Bristol Myers Squibb (BMY) posted disappointing results in the first quarter as the pharmaceutical company’s revenues rose 3% year-on-year to $11.1 billion, but …
Bristol-Myers Squibb has received approval from the US Food and Drug Administration for Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy to treat …
Bristol Myers Squibb and bluebird bio’s Abecma received approval from the U.S.
Bristol Myers Squibb, a biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …
Heat Biologics shares spiked 77% as the biopharma company reported positive interim data from the Phase 2 trial of its lung cancer treatment. …
Bristol Myers Squibb announced on Feb. 5 that the US Food and Drug Administration (FDA) has approved its lymphoma drug, Breyanzi, a CAR-T …
Bristol-Myers Squibb announced a $2 billion share buyback program, sending shares of the biopharmaceutical company up 4% on Monday. Bristol-Myers’ (BMY) additional share …
Bristol Myers Squibb (BMY) has announced that the U.S.
Bristol Myers Squibb (BMY) has announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a significant improvement in overall survival (OS) in patients with previously untreated, unresectable …
Biopharma AbbVie (ABBV) has announced positive Phase 3 data from a Select-Choice clinical trial, comparing Rinvoq (upadacitinib, 15 mg, once daily) to Bristol-Myers …
